Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 012 • 2020 Pediatric Rheumatology Symposium
Pediatric Antiphospholipid Syndrome: Clinical Features and Therapeutic Interventions in a Series of 22 Cases
Jacqueline Madison¹ and Jason Knight ¹, ¹University of Michigan, Ann Arbor
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…
Abstract Number: 133 • 2019 ACR/ARP Annual Meeting
Anti-β2GPI Domain 1 Antibodies Stratify High Risk of Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese Patients with Antiphospholipid Syndrome
Tingting Liu¹, Jieyu Gu ¹, Liyan Wan ¹, Gary L. Norman ², Hui Shi ¹ and Chengde Yang ¹, ¹Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²INOVA Diagnostics, Inc., CA 92131
Background/Purpose: Anti-β2GPI-Domain 1 (β2GPI -D1) antibodies are currently considered to be a pathogenic subset of anti-β2GPI antibodies and have been strongly associated with thrombosis and…
Abstract Number: 134 • 2019 ACR/ARP Annual Meeting
‘Non-criteria’ Antiphospholipid Antibodies Add Value to Antiphospholipid Syndrome Diagnoses in a Large Chinese Cohort
Jieyu Gu¹, Tingting Liu ¹, Liyan Wan ¹, Gary L. Norman ², Chengde Yang ¹ and Hui Shi ³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²INOVA Diagnostics, Inc., CA 92131, ³University of Michigan, Ann Arbor, MI
Background/Purpose: The laboratory criteria used in the 2006 Sydney Classification criteria for antiphospholipid syndrome (APS) which is widely used in clinical practice, includes IgG/IgM isotypes…
Abstract Number: 135 • 2019 ACR/ARP Annual Meeting
Added Clinical Utility of Testing for Extra-Criteria Antibodies Specificities Beyond Sapporo and Sydney Criteria Recommendations
Savino Sciascia¹, Irene Cecchi ², Massimo Radin ², Elena Rubini ², Silvia Grazietta Foddai ², Dario Roccatello ², Chelsea Bentow ³, Andrea Seaman ³, Carlos Ramirez ³ and Michael Mahler ³, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³Inova Diagnostics, San Diego, CA
Background/Purpose: The laboratory diagnostics of antiphospholipid syndrome (APS) takes into account the persistent positivity for anticardiolipin (aCL) and/or anti-β2glycoprotein I (anti-β2GPI) antibodies and/or the presence…
Abstract Number: 136 • 2019 ACR/ARP Annual Meeting
Identifying Phenotypes of Patients with Antiphospholipid Antibodies: Results from a Cluster Analysis in a Large Cohort of Patients
Savino Sciascia¹, Massimo Radin ², Irene Cecchi ², Maria Laura Bertolaccini ³, Tiziana Bertero ², Elena Rubini ², Antonella Vaccarino ², Mario Bazzan ², Osvaldo Giachino ², Simone Baldovino ², Daniela Rossi ², Giulio Mengozzi ² and Dario Roccatello ², ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³King's College London, London, United Kingdom
Background/Purpose: In this study, we sought to perform an unsupervised hierarchical clustering analysis in a large cohort of antiphospholipid antibodies (aPL) positive patients, to identify…
Abstract Number: 137 • 2019 ACR/ARP Annual Meeting
The Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Ecem Sevim¹, Diane Zisa ², Danieli Andrade ³, Vittorio Pengo ⁴, Savino Sciascia ⁵, Maria Tektonidou ⁶, Amaia Ugarte ⁷, Maria Gerosa ⁸, H Michael Belmont ⁹, Rosario Lopez Pedrera ¹⁰, Lanlan Ji ¹¹, Paul Fortin ¹², Maria Efthymiou ¹³, Guilherme De Jesus ¹⁴, David Branch ¹⁵, Laura Andreoli ¹⁶, Michelle Petri ¹⁷, Ricard Cervera ¹⁸, Esther Rodriguez ¹⁹, Jason Knight ²⁰, Tatsuya Atsumi ²¹, Rohan Willis ²², Maria Laura Bertolaccini ²³, Hannah Cohen ¹³, Robert Roubey ²⁴, Doruk Erkan ²⁵, Medha Barbhaiya ² and on Behalf of APS ACTION ²⁶, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁴Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ⁶First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁷Hospital Universitario Cruces, University of the Basque Country Autoimmune Diseases Research Unit, Department of Internal M edicine, BioCruces Health, Biscay, Spain, ⁸Istituto Ortopedico Gaetano Pini, University of Milan, Milan, Italy, ⁹NYU Langone Health, New York, NY, ¹⁰Maimonides Institute for Biomedical Research of Cordoba, Cordoba, Spain, ¹¹Peking University First Hospital, Beijing, China (People's Republic), ¹²Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹³University College London, London, United Kingdom, ¹⁴Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁶Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²¹Hokkaido University, Sapporo, Japan, ²²Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, ²³King's College London, London, United Kingdom, ²⁴The University of North Carolina at Chapel Hill, Chapel Hill, NC, ²⁵Hospital for Special Surgery, New York City, ²⁶APS ACTION, New York, NY
Background/Purpose: APS ACTION “Registry” was created to study the long-term natural history and outcomes of persistently antiphospholipid antibody (aPL)-positive patients with and without other systemic…
Abstract Number: 140 • 2019 ACR/ARP Annual Meeting
Early Anticoagulation Improves the Long-term Prognosis in Patients with Antiphospholipid Syndrome Associated Portal Vein Thrombosis
Hanxiao You¹, Jiuliang Zhao ², Xinping Tian ², Mengtao Li ³ and Xiaofeng Zeng ², ¹Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, China (People's Republic), ²Peking Union Medical College Hospital, Beijing, China (People's Republic), ³Dept. of Rheumatology, Peking Union Medical College Hospital (West Campus), Beijing, China, Beijing, China (People's Republic)
Background/Purpose: Portal vein thrombosis (PVT) is a rare and severe clinical phenotype of antiphospholipid syndrome (APS) with a poor prognosis. Anticoagulation therapy is efficient, but is associated with potentially…
Abstract Number: 142 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Antibodies Prevalence in Women with Late Pregnancy Complication and Low-Risk for Chromosomal Abnormalities
Silvia Grazietta Foddai¹, Massimo Radin ¹, Elena Rubini ¹, Irene Cecchi ¹, Savino Sciascia ², Dario Roccatello ¹, Elisa Menegatti ¹, Silvia Gaito ¹, Luca Marozio ¹, Tilde Manetta ¹ and Giulio Mengozzi ¹, ¹University of Turin, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
Background/Purpose: While current guidelines help defining correct pregnancy standard of care for patients with systemic lupus erythematosus andantiphospholipid syndrome (APS),little is known about the significance…
Abstract Number: 144 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Syndrome-Associated Preeclampsia Is Defined by a Distinct Clinical Phenotype
Shashank Cheemalavagu¹, Beth Wallace ², Wendy Marder ³, Jason Knight ⁴ and Andrew Vreede ⁵, ¹Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, ⁴Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁵Division of Rheumatology, Department of Internal Medicine, Michigan Medicine; Rheumatology Section, VA Ann Arbor Health System, Ann Arbor, MI
Background/Purpose: Antiphospholipid syndrome (APS) significantly increases risk of preeclampsia. It is assumed that APS is associated with a subset of severe preeclampsia, HELLP (Hemolysis; Elevated…
Abstract Number: 19 • 2019 ACR/ARP Annual Meeting
Inhibition of IkB Kinase-IKK Complex of Canonical NF-κB Pathway in Antiphospholipid Antibody-Mediated Endothelial Cell Activation
Rohan Willis¹, Elizabeth Papalardo ¹, Mohammad Jamaluddin ¹, Zurina Romay-Penabad ¹, Alvaro Schleh ¹, Allan Brasier ¹ and Emilio B Gonzalez ², ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, Galveston
Background/Purpose: Antiphospholipid antibodies (aPL) activate several target cell types leading to inflammatory damage and thrombosis in the antiphospholipid syndrome (APS). NF-κB activation is essential for…
Abstract Number: 305 • 2019 ACR/ARP Annual Meeting
Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing
Caleb Anderson¹, Roger Stitt ² and Robert O'Brian ¹, ¹Walter Reed National Military Medical Center, Bethesda, MD, ²US Army, Ft Eustis
Background/Purpose: Greater emphasis has been placed on cost saving measures due to ballooning healthcare cost in the U.S. ACGME now evaluates trainee ability to practice…
Abstract Number: 20 • 2019 ACR/ARP Annual Meeting
Comparative Efficacy of Beta-2-Glycoprotein I Domain V Structural Analogue Variants in Preventing Antiphospholipid Antibody-Mediated Endothelial Cell Activation
Rohan Willis¹, Elizabeth Papalardo ¹, Mohammad Jamaluddin ¹, Zurina Romay-Penabad ¹, Alvaro Schleh ¹, Allan Brasier ¹ and Emilio B Gonzalez ², ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, Galveston
Background/Purpose: In previous studies, our group has demonstrated that a synthetic 20 amino acid peptide (“TIFI”) with structural similarity to Beta-2-Glycoprotein I Domain V (β2GPI…
Abstract Number: 1788 • 2019 ACR/ARP Annual Meeting
Anti-neutrophil Extracellular Trap (NET) Autoantibodies in Primary Antiphospholipid Syndrome
Yu Zuo¹, Srilakshmi Yalavarthi ², Kelsey Gockman ², David Karp ³, Quan-Zhen Li ⁴ and Jason Knight ⁵, ¹University of Texas Southwestern, Dallas, TX, ²University of Michigan, Ann Arbor, MI, ³UTSouthwestern Medical Center, Dallas, TX, ⁴Department of Immunology & Internal Medicine/University of Texas Southwestern Medical Center, Charleston, ⁵Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Neutrophil extracellular traps (NETs) are prothrombotic tangles of chromatin and microbicidal proteins ejected from neutrophils in response to a variety of stimuli. In antiphospholipid…
Abstract Number: 73 • 2019 ACR/ARP Annual Meeting
Potent Anti-neutrophil Properties of the Natural Compound 6-Gingerol in Models of Lupus and Antiphospholipid Syndrome
Ramadan Ali¹, Julia Weiner ¹, Alex Gandhi ¹, Shanea Estes ¹ and Jason Knight ², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: 6-gingerol, the major bioactive compound of ginger root, is known to have anti-inflammatory and anti-oxidative effects. Indeed, ginger has been employed for millennia as…
Abstract Number: 1792 • 2019 ACR/ARP Annual Meeting
Cognitive Dysfunction (CD) and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Primary Antiphospholipid Syndrome (PAPS)
Renata Rosa¹, Michelle Remião Ugolini-Lopes ², Ana Paula Gandara ², Kenia Campanholo ², Livia Dutra ³ and Danieli Andrade ⁴, ¹Faculdade de Medicina da Universidade de São Paulo (USP), Brazil., São Paulo, Sao Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo (USP), Brazil., São Paulo, Brazil, ³Escola Paulista de Medicina (EPM), Brazil, São Paulo, Brazil, ⁴Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: Cognition dysfunction (CD) is a poorly understood non-stroke central neurologic manifestation of antiphospholipid syndrome, whose diagnosis involves a specific neuropsychological (NP) evaluation. Brain-derived neurotrophic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].